Australia markets open in 4 hours 43 minutes

Zhejiang Xinguang Pharmaceutical Co., Ltd. (300519.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
10.96+0.40 (+3.79%)
At close: 03:04PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 1.69B
Enterprise value 953.76M
Trailing P/E 30.17
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.12
Price/book (mrq)1.95
Enterprise value/revenue 3.42
Enterprise value/EBITDA 23.17

Trading information

Stock price history

Beta (5Y monthly) 0.20
52-week change 3-32.35%
S&P500 52-week change 324.96%
52-week high 319.88
52-week low 38.45
50-day moving average 312.06
200-day moving average 314.24

Share statistics

Avg vol (3-month) 32.06M
Avg vol (10-day) 31.31M
Shares outstanding 5160M
Implied shares outstanding 6160.28M
Float 870.57M
% held by insiders 158.65%
% held by institutions 11.48%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.4
Forward annual dividend yield 43.79%
Trailing annual dividend rate 30.40
Trailing annual dividend yield 33.79%
5-year average dividend yield 43.09
Payout ratio 4142.86%
Dividend date 3N/A
Ex-dividend date 429 May 2024
Last split factor 220:10
Last split date 304 July 2017

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 20.36%
Operating margin (ttm)23.34%

Management effectiveness

Return on assets (ttm)2.50%
Return on equity (ttm)6.46%

Income statement

Revenue (ttm)278.65M
Revenue per share (ttm)1.72
Quarterly revenue growth (yoy)8.90%
Gross profit (ttm)N/A
EBITDA 53.1M
Net income avi to common (ttm)56.74M
Diluted EPS (ttm)0.36
Quarterly earnings growth (yoy)-25.00%

Balance sheet

Total cash (mrq)735.84M
Total cash per share (mrq)4.6
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)11.54
Book value per share (mrq)5.42

Cash flow statement

Operating cash flow (ttm)64.13M
Levered free cash flow (ttm)19.18M